Document is current
Any future updates will be listed below
-
Authors
Taguchi, Ayumi
Rokutan, Hirofumi
Oda, Katsutoshi http://orcid.org/0000-0002-2468-9573
Tanikawa, Michihiro
Tanimoto, Saki
Sone, Kenbun
Mori, Mayuyo
Tsuruga, Tetsushi
Kohsaka, Shinji
Tatsuno, Kenji
Shinozaki-Ushiku, Aya
Miyagawa, Kiyoshi
Mano, Hiroyuki
Aburatani, Hiroyuki
Ushiku, Tetsuo
Osuga, Yutaka
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP19kk0205016)
- License Information
-
More Information
Article History
Received: 25 August 2021
Accepted: 18 February 2022
First Online: 7 March 2022
Declarations
:
: This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Institutional Ethics Committee of the University of Tokyo (G10114-15).
: We obtained written informed consent for publication of all clinical information from the patient. As well, written consent for publication of identifying images, other personal and clinical details was obtained from the next of kin.
: Dr. Oda received a research grant from Konica Minolta, INC. and AstraZenea plc., and lecture fees from Chugai Pharmaceutical Co., Ltd. and AstraZenea plc. Dr. Aburatani received grants from Sysmex Corporation and the Japan Agency for Medical Research and Development (AMED) during the study. Dr. Mano received grants from Sysmex Corporation during the study, and from Konica Minolta, outside the submitted work. In addition, Dr. Mano and Dr. Kohsaka have a patent IP for design and analytical methods related to Todai OncoPanel issued to the University of Tokyo. The sequencing analysis and interpretation of the data were performed under a grant from the Program for an Integrated Database of Clinical and Genomic Information (JP19kk0205016) from the Japan Agency for Medical Research and Development and a grant by Sysmex Corporation. The other authors have no conflicts of interest to disclose.
